Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
10. August 2023 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
08. August 2023 07:00 ET
|
Entrada Therapeutics, Inc.
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 – – $377 million in cash, cash equivalents and marketable securities as of June 30,...
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
01. August 2023 07:00 ET
|
Entrada Therapeutics, Inc.
– First participant is expected to be dosed in September 2023 with data anticipated in the second half of 2024 – – Cash runway extended through the end of 2025 – BOSTON, Aug. 01, 2023 (GLOBE...
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
06. Juni 2023 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular...
Entrada Therapeutics Reports First Quarter 2023 Financial Results
10. Mai 2023 07:00 ET
|
Entrada Therapeutics, Inc.
- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 -- Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics,...
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
04. April 2023 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
29. März 2023 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
06. März 2023 07:00 ET
|
Entrada Therapeutics, Inc.
- Established a transformative collaboration with Vertex to discover and develop intracellular Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1 - - Actively working to resolve the...
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
27. Februar 2023 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular...
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
09. Februar 2023 07:00 ET
|
Entrada Therapeutics, Inc.
- Global collaboration includes ENTR-701, Entrada’s late-stage preclinical candidate for the treatment of DM1 - - Company’s cash runway extended into the second half of 2025 - BOSTON, Feb. 09, 2023...